UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK.
Department of Cellular Pathology, Royal Free Hospital, London, UK.
Aliment Pharmacol Ther. 2019 May;49(9):1214-1222. doi: 10.1111/apt.15219. Epub 2019 Mar 18.
Collagen proportionate area (CPA) measurement is a technique that quantifies fibrous tissue in liver biopsies by measuring the amount of collagen deposition as a proportion of the total biopsy area. CPA predicts clinical outcomes in patients with HCV and can sub-classify cirrhosis.
To test the ability of CPA to quantify fibrosis and predict clinical outcomes in patients with NAFLD.
We assessed consecutive patients with biopsy-proven NAFLD from three European centres. Clinical and laboratory data were collected at baseline and at the time of the last clinical follow-up or death. CPA was performed at two different objective magnifications, whole biopsy macro and ×4 objective magnification, named standard (SM) and high (HM) magnification respectively. The correlation between CPA and liver stiffness was assessed in a sub-group of patients.
Of 437 patients, 32 (7.3%) decompensated and/or died from liver-related causes during a median follow-up of 103 months. CPA correlated with liver stiffness and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was significantly higher than SM CPA in stages F0-F3 but similar in cirrhosis, reflecting a higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at baseline (HR: 1.04, 95% CI: 1.01-1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI: 1.01-1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02-47.84) were independent predictors of liver-related clinical outcomes at standard and competing risk multivariate Cox-regression analysis.
CPA accurately measures fibrosis and is an independent predictor of clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate endpoint in clinical trials.
胶原比例面积(CPA)测量是一种通过测量胶原沉积量占活检总面积的比例来量化肝活检中纤维组织的技术。CPA 可预测 HCV 患者的临床结局,并可对肝硬化进行亚分类。
检验 CPA 量化非酒精性脂肪性肝病(NAFLD)患者纤维化程度和预测临床结局的能力。
我们评估了来自三个欧洲中心的经活检证实的 NAFLD 连续患者。临床和实验室数据在基线和最后一次临床随访或死亡时收集。CPA 在两个不同的客观放大倍数下进行,即整个活检宏观和×4 物镜放大倍数,分别命名为标准(SM)和高(HM)放大倍数。在一组患者中评估了 CPA 与肝硬度之间的相关性。
在中位随访 103 个月期间,437 例患者中有 32 例(7.3%)因肝脏相关原因失代偿和/或死亡。CPA 与整个纤维化谱中的肝硬度和纤维化分期相关。HM-CPA 在 F0-F3 期明显高于 SM-CPA,但在肝硬化中相似,反映了在早期阶段更能捕捉到细胞周/窦周纤维化。基线时的年龄(HR:1.04,95%CI:1.01-1.08)、HM-CPA(HR:每增加 1%,95%CI:1.01-1.08)和存在晚期纤维化(HR:15.4,95%CI:5.02-47.84)是标准和竞争风险多变量 Cox 回归分析中肝脏相关临床结局的独立预测因素。
CPA 能准确测量纤维化,是 NAFLD 临床结局的独立预测因素;因此,它值得作为临床试验中的替代终点进一步评估。